Key result
Cardiac screening using novel imaging technology prior to hematopoietic stem-cell transplantation may improve risk stratification and decrease cardiovascular morbidity and mortality.
Why the study?
Hematopoietic stem-cell transplantation can cause life-threatening cardiovascular complications, making pretransplant cardiac risk stratification important to identify patients likely to tolerate potential toxicities.
Novel imaging technologies may improve pre-transplant cardiac risk stratification for patients undergoing hematopoietic stem-cell transplantation, potentially reducing cardiovascular morbidity and mortality.
Hematopoietic stem-cell transplantation (HSCT) is a complex procedure that has been increasingly successful in treating malignant and nonmalignant conditions. Despite its effectiveness, it can be associated with potentially life-threatening adverse effects. New onset heart failure, ischemic disease, and arrhythmias are among the most notable cardiovascular complications post-HSCT. As a result, appropriate cardiac risk stratification prior to transplant could result in decreased morbidity and mortality by identifying patients with a higher probability of tolerating possible toxicities associated with HSCT. In this review, we aim to discuss the utility of cardiac screening using novel modalities of imaging technology in the pre-HSCT phase.
No takes yet. Share an insight, caveat, or question.
Hemu et al. (2019) conducted a review in Hematopoietic stem-cell transplantation (HSCT) candidates. Cardiac screening using novel modalities of imaging technology was evaluated. Cardiac screening using novel imaging technology prior to hematopoietic stem-cell transplantation may improve risk stratification and decrease cardiovascular morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: